HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US OTC Monograph FY2022 Facility Fees Deadline In June At Amount TBD

Executive Summary

Firms making OTC monograph drugs won’t have to pay facility fees twice during FY2021, says Theresa Michele, FDA Office of Nonprescription Drugs director.

You may also be interested in...



'Milestone' Discussions With US FDA On OTC Monograph Proposals Limited To One Meeting

Recent draft guidance on scheduling and conducting meetings with FDA supported by OTC monograph user fees largely tracks with agency’s guidance for meetings supported by other user fee programs, such as PDUFA.

US FDA OTC Monograph Meetings Guidance Should Be Familiar To Firms Using NDA Pathway

Recent draft guidance on scheduling FDA meetings to discuss potential OTC monograph order requests marks step in program overhaul authorized in 2020 legislation, but isn’t a signal for manufacturers, other industry stakeholders to expect meetings soon.

Drug Firms Have More Time For First Annual Report On Production Volumes US Is Requiring

FDA announces day before due date that as it continues considering comments to a draft guidance on the requirement it published in October, the “document is not a binding document” and “the recommended … reporting date for 2020 data is not a requirement.”

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel